

Peter Carson, MD

INFORMATION:

Office Address: Medical Intensive Care Unit
Veterans Affairs Medical Center
50 Irving Street, N.W.
Washington, DC 20422
(202) 745-8109

CERTIFICATION: Board Certification: American Board of Internal Medicine
Date of Certification: 09/15/1982
Date of Re-certification: Indefinitely

Specialty Board: Cardiovascular Disease
Date of Certification: 11/11/1987
Date of Re-certification: Indefinitely

EDUCATION: Undergraduate: University of North Carolina
Chapel Hill, North Carolina
1968 - 1973
Bachelor of Arts, cum laude

Medical Education: University of North Carolina
Chapel Hill, North Carolina
1973-1977
M.D., cum laude

Internship: University of Texas Health Science Center
Internal Medicine
San Antonio, Texas
1979 - 1980
Department Chair: Jay Stein M.D.

Residency: Case Western Reserve University Medical
School, University-Hospital
Internal Medicine
Cleveland, Ohio
1980 - 1982
Department Chair: Charles C.J Carpenter
M.D.

Fellowship: University of Minnesota School of Medicine
Cardiology
Minneapolis, Minnesota
1983 -1986
Department Chair: Thomas Ferris M.D.

Fellowship: University of North Carolina School of
Medicine
Research Assistant
Chapel Hill, North Carolina
1974 - 1975

University of North Carolina School of
Medicine
Summer Research Fellow
Chapel Hill, North Carolina
1976

**PROFESSIONAL
EXPERIENCE: -**

2010
Professor of Medicine
Georgetown University
Washington, D.C.

1996
Associate Professor of Medicine
Georgetown University
Washington, D.C.

1994
Co-Director, Heart Failure Service
Georgetown University
Washington, D.C.

1989-present
Chief, Medical Intensive Care Unit
Veterans Affairs Medical Center
Washington, DC

1989 – present
Staff Physician
Georgetown University Hospital
Washington, D.C.

1988 - 1989

Private Practice
Washington, D.C. and Northern Virginia

1987 - 1988
Title: Chief Coronary Care Unit
Detroit Receiving Hospital
Detroit, Michigan

1986 - 1988
Staff Cardiologist
Wayne State University
Detroit, Michigan

1986 – 1987
Staff Physician, Division of Cardiology
Harper Hospital
Detroit, Michigan

1986 - 1988
Instructor, School of Medicine
Wayne State University
Detroit, Michigan

1984 - 1986
University of Minnesota
Minneapolis, Minnesota
School of Medicine
Instructor

1982 - 1983
Instructor, School of Medicine
Case Western Reserve
Cleveland, Ohio

1982 – 1983
Staff Physician
Cleveland Metropolitan Hospital
Cleveland, Ohio

1982 – 1983
Firm Director, Department of Medicine
Cleveland Metropolitan Hospital
Cleveland, Ohio

**HONORS and
AWARDS:**

1968 - 1972
Dean's List,

University of North Carolina

PROFESSIONAL SOCIETIES:

1982 – 1983, Member, Cuyahoga County Medical Society, Past

1983 – 1986, Member, Hennepin County Medical Society, Past
1986- present , Member, American Heart Association

1986- present , Member, American College of Cardiology

1997- present, Member, Heart Failure Society of America

Date, Fellow, American College of Cardiology

PUBLIC SERVICE:
list professional service
on editorial boards,
Study Sections, as well
as any community or
public service (national
and international
organizations)

Reviewer
Journal of Congestive Heart Failure
2000-Present

Reviewer
American Heart Journal
2001-Present

Reviewer
JACC
2000-Present

Reviewer
Circulation
2001-present

Abstract Reviewer
American Heart Association
1994 – Present

Abstract Reviewer
American College of Cardiology
1996 - Present

Abstract Reviewer
Heart Failure Society America
1998 – Present

Member
Planning Committee, Veterans Affairs Cooperative Study #368 -
VANQUISH Trial

1991

Member

Executive Committee, Veterans Affairs Cooperative Study #368

VANQUISH Trial

1992 – 1996

Member

Planning Committee, Veterans Affairs Cooperative Study #395

Beta Blocker Evaluation Survival Trial – “BEST”

1992 - 1993

Member

Endpoints Committee, PRAISE Study

1993 -1995

Member

Steering Committee, NIH-Veterans Affairs Cooperative Study

"BEST"

1993 - 1999

Member

Endpoints Committee, "VEST"

1995 - 1998

Co-Chairmen

Endpoints Committee, "BEST"

1995 – 1998

Member

Steering Committee, PRAISE II Study

1995 - 2000

Chairman

Endpoints Committee Val HeFT

1997 - 2000

Chairman

Events Committee, COPERNICUS

1997 - 2000

Member

Endpoint Committee RENAISSANCE/RECOVER

1998 – 2002

Member

Endpoint Committee OVERTURE
1999 – 2002

Member
Chairman Endpoint Committee COMPANION
2000 - 2004

Member
DATA Monitoring Board CSP #410 FEAST
2000 - present

Chairman
Endpoints Committee EMOTE
2001 - 2004

Member
Endpoints Committee ESSENTIAL
2002 - 2004

Chairman
Endpoint Committee AAHeFT
2002 – 2004

Member
HFSA Program Committee
2002-2004

Co - principal Investigator
I-PRESERVE
2002 - 2010

Member
Endpoints Committee FUSION II
2004 - 2007

Member
Endpoints Committee EVEREST
2004 - 2007

Member
Endpoints Committee ORQIS
2004 – 2006

Chairman
Endpoints Committee STICH
2004- 2011

Member
Data Monitoring Board RED-HF
2006 – 2012

Chairman
Endpoints Committee PRECEDE
2007- 2009

Member
Endpoints Committee PROTECT
2007- 2009

Member
Endpoints Committee CHAMPION
2007 – 2011

Member
Endpoints Committee HOPE4F
2009 - 2010

HFSA Guidelines Committee
2010 -present

Member
Endpoints committee LAPTOP study
2011-2015

Member
Endpoint Committee RELAX AHF 2
2013 – present

Member
Endpoint committee RESPCARDIA pivotal study
2014-present

Member
Endpoint committee PREserve AMI
2014

Chairman
Data Monitoring Board OCEAN Trial

2014- 2015

Chairman
Endpoint Committee CAT-HF
2014- 2016

Chairman
Endpoint Committee STICHES
2014 –present

Chairman
Endpoint Committee – RELAX Asia
2014 –present

Member
Endpoint Committee CardioMems
2015 – present

Chairman
Endpoint Committee FIX-HF-5C
2015 – present

Member
Data Member – PRIME-HF
2016 -

**INVITED
LECTURES:**

Co-Chairman, Clinical Trials Session
American Heart Association - Anaheim, CA
November 1995

Calcium Channel Antagonists in Heart Failure: Results of the
PRAISE Trial
Argentine Congress of Cardiology - Buenos Aires, Argentina
October 1996

Heart Failure: Results of PRAISE.
Portuguese Heart Association - Oporto, Portugal
November 1996

Co-Chairman, Beta-Blocker in Heart Failure
American College of Cardiology
November 1996

Beta Blocker Therapy in Heart Failure
UMDNJ
January 1997

Calcium Channel Blockers in Heart Failure
Thailand Heart Association - Bangkok, Thailand
March 1997

Medical Economic Issues in Heart Failure
American College of Cardiology Symposium - Anaheim CA
March 1997

B Symposium –eta Blockers in Heart Failure
Fifth International Heart Failure - Washington, DC
May 1997

Symposium –Advances in Beta Blocker Therapy
Heart Failure Society America - Baltimore, MD
September 1997

Case Presentation: Beta Blockade in Heart Failure
American Heart Association Symposium - Orlando FL
November 1997

Cardiology Grand Rounds - New Concepts in Heart Failure
University of California, Irvine
November 1997

Symposium – Peripheral Syndromes of Heart Failure
American College of Cardiology - New Orleans LA
March 1998

Ischemic and Hypertension Effects
Philippine National Congress of Cardiology - Manila, Philippines
May 1998

Symposium – Clinical use of Calcium Channel Blocker.
American Society of Hypertension
May 1998

Symposium – Beta-Blockers in Heart Failure
Fifth International Heart Failure - Geneva Switzerland

May 1998

Pathophysiology of Heart Failure.
Argentina National Congress - Buenos Aires Argentina
June 1998

Moderator – Clinical Trial Workshop
Heart Failure Society America - Boca Raton FL
September 1998

Co-Chairman, Transplant issues and Heart Failure
American Heart Association – Dallas Texas
November 1998

Symposium – Clinical use of Beta. Blockers in Heart Failure
European Society of Cardiology - Barcelona, Spain
August 1999

Symposium – Implementing Therapy with Beta-Blockers
European Society Cardiology - Barcelona, Spain
August 1999

Symposium – Angiotensin Receptor Blockers in Heart Failure
Brazil Congress of Cardiology - Recife, Brazil
September 1999

Symposium – Clinical Trials of Angiotensin Receptor Blockers in
Heart Failure
Heart Failure Society America – San Francisco, CA
September 1999

Symposium – Angiotensin Receptor Blockers in Heart Failure
Turkish Congress of Cardiology – Izmir Turkey
October 1999

Symposium – Calcium Channel Antagonists in Heart Failure:
PRAISE
Advanced Drug Research in Cardiology – 3rd International Meeting
Monte Carlo, Monaco
December 1999

Co-Chairman. Heart Failure with Preserved Systolic Function
American College of Cardiology - Anaheim CA
March 2000

Symposium Beta - Blocker The Optimal Therapy for Heart Failure.

Egyptian National Congress of Cardiology - Cairo Egypt
February 2000

Symposium – Clinical Trials
European Society of Cardiology – Amsterdam Holland
August 2000

Angiotensin Receptor Blockers
Brazilian Congress of Cardiology - Rio De Janeiro Brazil
August 2000

Plenary Session: Racial Difference in Response in Heart Failure
Therapy
Heart Failure Society of America - Boca Raton Florida
September 2000

Symposium – System Burden of Heart Failure
Fourth International Annual Renin Angiotensin - Monte Carlo,
Monaco
January 2001

Symposium
Asia Pacific Cardiology Congress - Bali Indonesia
May 2001

Moderator Clinical Trials - Late Breaking Heart Failure
Society of America - Washington DC
September 2001

Clinical Trials Symposium
Asia/Pacific Society of Cardiology - Hong Kong
Nov 2001

Symposium – Clinical Trials
European Society of Cardiology - Stockholm, Sweden
August 2001

Symposium – Clinical Trials.
European Society of Cardiology - Berlin, Germany
August 2002

Symposium – Clinical Trials
European Society of Cardiology – Vienna, Austria
August 2003

Symposium – Clinical Trials

European Society of Cardiology – Munich, Germany
August 2004

Symposium -- Clinical Trials
European Society of Cardiology – Barcelona, Spain
September 2006

Discussant – Late Breaking Clinical Trials
America College of Cardiology - Atlanta, Georgia
March 2008

Symposium – Clinical Trials
European Society of Cardiology – Munich, Germany
September 2008

Late Breaking Clinical Trials
American Heart Association – New Orleans , Louisiana
November 2008

Keynote Address
Taiwan Cardiology Society – Taipei, Taiwan
December 2008

Late Breaking Clinical Trials
Japan Circulation Society – Osaka Japan
March 2009

**UNIVERSITY
SERVICE:**

Department

Chairman
Critical Care Committee, Detroit Receiving Hospital
1987 - 1989

Chairman
Code Blue Committee, Veterans Affairs Medical Center,
1989 - 2005

Chairman
Medical Intensive Care Unit Committee, Veterans Affairs Medical
Center
1989 – present

Member
Institutional Review Board (IRB), Veterans Affairs Medical Center
1992 – 1994

Member
Medical Primary Care Committee, Veterans Affairs Medical Center
1994 – 1997

Member
Education and Development Committee, Veterans Affairs Medical
Center
1996 – 1997

Research and Development (R&D Committee), Veterans Affairs
Medical Center
2004 - Present

University

Member
Georgetown-Washington Hospital Center, Fellowship Selection
Committee
2007– Present

**TEACHING
ACTIVITIES:**

Clerkships

Name of Clerkship: Coronary Care Unit
Role: Attending
Number of Direct Contact Hours*: 2-4 months/year; 8 additional
weekends/year
Year Taught: 1989 to present
Number of Students/House staff/fellow: 6-10

Name of Clerkship: General Medical Wards
Role: Attending
Number of Direct Contact Hours*: 2 weeks/year
Year Taught: 2000 to present
Number of Students/House staff: 2-4

Course/Clerkship Directorships

Currently formulating a Cardiology elective for Georgetown George
Washington House Staff and Students

Average number of Fellows you train per year = 12
Average number of Residents you train per year = 30

SCHOLARSHIP

RESEARCH GRANTS

AND RESEARCH:

Previous

Agency: VAMC Washington, DC

Title of Project: Multicenter, randomized, double blind, placebo-controlled study of the effects of KW-3902 injectable emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure syndrome and renal impairment who are hospitalized for volume overload and require intravenous diuretic therapy.

Dates of Project Period: 2008-2009

Role on Project: Principal Investigator

Agency: VAMC Washington, DC

Title of Project: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM

Dates of Project Period: 1999 - 2003

Role on Project: PI

Agency: VAMC Washington, DC

Title of Project: Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH)

Dates of Project Period: 1999-2004

Role on Project: PI

Agency: VAMC Washington, DC

Title of Project: Effect of Moxonidine in Chronic Heart Failure (MOXCON)

Dates of Project Period: 1998-1999

Role on Project: PI

Agency: VAMC Washington, DC

Title of Project: Effect of Carvedilol on Survival In Severe Heart Failure (COPERNICUS)

Dates of Project Period: 1997-2000

Role on Project: PI

Title of Project: PRAISE II - A Randomized, Double-Blind, Dose-Titration, Parallel Group, Placebo-Controlled Study to Evaluate the Effects of Amlodipine on Mortality and Morbidity in Patients with Severe Heart Failure

Dates of Project Period: 1996-2000

Role on Project: PI

Agency: VAMC, Washington, DC- Georgetown University
Medical

Identifying Number:

Title of Project: BEST - Beta Blocker Evaluation of Survival Trial (BEST) - VA Cooperative Trial

Dates of Project Period: 1995-1999

Role on Project: Co PI

Agency: Georgetown University Medical Center & VAMC, Washington, DC

Identifying Number:

Title of Project: VEST - A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of the Chronic Administration of Vesnarinone in Heart Failure

Dates of Project Period: 1995-1998

Role on Project: PI

Agency: VAMC Washington, DC

Identifying Number:

Title of Project: BEST – Beta-Blocker Evaluation of Survival Trial (BEST) VA Cooperative Trial

Dates of Project Period: 1995-1999

Role on Project:

Agency: VAMC Washington, DC

Identifying Number:

Title of Project: VEST - A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of the Chronic Administration of Vesnarinone in Heart Failure

Dates of Project Period: 1990-1995

Role on Project: PI

Agency: Fairfax Hospital Fairfax, VA

Identifying Number:

Title of Project: Carvedilol in Heart Failure: A Six Month, Double-Blind, Multicenter Comparison of Oral Carvedilol with Placebo in Patients with Congestive Heart Failure

Dates of Project Period: 1993-1995

Role on Project: PI

Agency: MACH-1 Washington VAMC

Identifying Number:

Title of Project: The Effect of RO-40-5967 on CTT Duration and on All Causes of Mortality in Comparison with Placebo in Patients with Chronic Heart Failure.

Dates of Project Period: 1994-1998

Role on Project:

Agency: VAMC Washington, DC
Identifying Number:
Title of Project: Randomized, Double-Blind, Dose Response, Positive Control Comparative Evaluation of the Efficacy and Safety of OPC-18790 in the Treatment of Patients with Decompensated Heart Failure
Dates of Project Period: 1994-1995
Role on Project: PI

Agency: Fairfax Hospital Fairfax, VA
Identifying Number:
Title of Project: Flolan in Heart Failure Survival Trial (FIRST).
Dates of Project Period: 1993-1994
Role on Project: Co PI

Agency: VAMC Washington, DC
Identifying Number:
Title of Project: Assessment of Treatment with Lisinopril and Survival (ATLAS)
Dates of Project Period: 1993-1998
Role on Project: PI

Agency: VAMC Washington, DC
Identifying Number:
Title of Project: A Double-Blind, Randomized Exercise Study of Low and Intermediate Dose of OPC-8212 in Heart Failure
Dates of Project Period: 1993-1994
Role on Project: PI

Agency: VAMC Washington, DC
Identifying Number:
Title of Project: Evaluation of the Hemodynamic Effects and Safety of Amlodipine in Patients with Stable Heart Failure (NYHA II-IV).
Dates of Project Period: 1992-1993
Role on Project: PI

Agency: VAMC Washington, DC
Identifying Number:
Title of Project: A Phase 2 Double-Blind, Placebo-Controlled Study of the Pharmacodynamics and Pharmacokinetics of OPC-18790 in Patients with Heart Failure
Dates of Project Period: 1992-1993
Role on Project: PI

Agency: VAMC Washington, DC

Identifying Number:

Title of Project: A Double-Blind, Randomized, Placebo-Controlled Study of the Hemodynamic Effects of Felodipine ER in Patients with Heart Failure.

Dates of Project Period: 1992-1993

Role on Project: PI

Agency: VAMC Washington, DC

Identifying Number:

Title of Project: A Double Blind, Randomized Study Comparing the First Dose Effects of Enalapril and Captopril in Congestive Heart Failure

Dates of Project Period: 1991-1992

Role on Project: PI

Agency:

Identifying Number: Fairfax Hospital Fairfax, VA

Title of Project: A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of the Chronic Administration of OPC-8212 In Chronic Heart Failure.

Dates of Project Period: 1990-1992

Role on Project: Co PI

Agency: VAMC Washington, DC

Identifying Number:

Title of Project: A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study of the Chronic Administration of OPC-8212 in Heart Failure

Dates of Project Period: 1990-1992

Role on Project: PI

Agency: Washington VAMC

Title of Project: A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety of and Efficacy of Felodipine ER in patients with Heart Failure (V-HeFT III).

Dates of Project Period: 1993 -4

Role on Project: Principal Investigator

Agency: Washington VAMC

Title of Project: PRAISE - A Randomized, Double-Blind, Dose-Titration, Parallel Group, Placebo Controlled Study to Evaluate the Effects of Amlodipine on Mortality and Morbidity in Patients with Severe Heart Failure

Dates of Project Period: 1992 -1994

Role on Project: Principal Investigator

Agency: VAMC Washington, DC
Identifying Number:
Title of Project: Vasodilator Therapy in Chronic
Congestive Heart Failure (V-HEFT II).
Dates of Project Period: 1989-1992
Role on Project: Principal Investigator

Agency: VAMC Washington, DC
Identifying Number:
Title of Project: A multicenter, randomized, double-blind, double
dummy, parallel group, active-controlled to evaluate the effect of
sacubitril-valsartan (LCZ696) versus enalapril in-hospital initiation
of LCZ696 compared to enalapril in HFrEF patients acute
decompensated heart failure (ADHF) (PIONEER)
Dates of Project Period: 2016- current
Role on Project: Principal Investigator
Agency: VAMC Washington, DC
Identifying Number:
Title of Project A Study of Vericiguat in Participants With Heart
Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
(VICTORIA)
Dates of Project Period: 2016- current
Role on Project: Principal Investigator

PUBLICATIONS – list publications in chronological order and
provided only works which have been accepted for publication. Do
NOT include “manuscripts in preparation” or “manuscripts
submitted for publication”. Publications should be listed separately
for the categories listed below.

Original Papers in Refereed Journals

List authors in order of appearance on paper: Last name, Initials,
Title of paper, *Journal name*, volume: first and last page numbers,
year.

1. Carson PE, Carlyle PF, Cohn JN: Cardiac and Regional Vascular
Effects of Atrial Natriuretic Peptide in Awake Dogs with Left
Ventricular Dysfunction. *Trans Assoc Amer Phys* 1986;49:34-38
2. Carson PE, Carlyle PF, Cohn JN: Hemodynamic, Renal and
Neurohumoral Response to Atrial Natriuretic Peptide in the
Conscious Dog. In *Biologically Active Atrial Peptide*. Brennar B,
ed. *Amer J of Pharm* 1987;1:322-324.
3. Carson PE, Carlyle PF, Cohn JN: Cardiac and Regional Vascular

Effects of Atrial Natriuretic Peptide in the Conscious Dog with and without Chronic Left Ventricular Dysfunction. *Journal of Cardiovascular Pharmacology* 1990;16:305-311.

4. Herzog CA, Carson PE, Michaud L, Asinger RW: Two Dimensional Echocardiographic Imaging of Left Ventricular Mural Vegetation. *Am Heart J* 1988;115:684-686.

5. Mehta P, Reddy B, Lesser J, Carson P: Bradyarrhythmia Following Electrical Cardioversion for Atrial Tachyarrhythmia in Patients with Acute Myocardial Infarction. *Chest* 1990;97:241-242.

6. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman BW, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Carson PE, Cintron G, Shabetai R: Enalapril vs. Hydralazine-Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure. *N Engl J Med* 1991;325:303-310.

7. Carson PE, Johnson G, Dunkman WB, Cohn JN, and the V-HeFT Investigators: Effects of Atrial Fibrillation on Prognosis in Heart Failure (V-HeFT Study). *Circulation* 1993;87:102-110.

8. Johnson G, Carson PE, Cohn JN for the VA Cooperative Study Group: Influence of Pre-Randomization (Baseline) Variables on Mortality and on the Reduction of Mortality by Enalapril. *Circulation* 1993;87:V132-V139.

9. Dunkman WB, Johnson GR, Carson PE, Cohn JN for the V-HeFT Study Group: Incidence of Thromboembolic Events in Congestive Heart Failure. *Circulation* 1993;87:94-101.

10. Fletcher RD, Cintron GB, Johnson G, Orndorff J, Carson PE, Cohn JN: Enalapril Decreases Prevalence of Ventricular Tachycardia in Patients with Congestive Heart Failure. *Circulation* 1993;87:49-55.

11. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, White BG: Results of a Multicenter Study of OPC-8212 in Chronic Congestive Heart Failure. *N Engl J Med* 1993;329:149-155.

12. Szyniszewski AM, Carson PE, Sakwas M, Lundstrom T, Boden WE: Valve Replacement for Tricuspid Regurgitation Appearing Late After Healing of Posterior Wall and Right Ventricular Acute Myocardial Infarction. *Am J Cardiol* 1994;73:616-617.

13. Anderson JL, Platia EV, Hallstrom A, Henthorn RW, Buckingham TA, Carlson MD, Carson PE for the Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Interaction of Baseline Characteristics with the Hazard of Encainide/lecainide and Morcizine Therapy in Patients with Myocardial Infarction: A Possible Explanation for Increased Mortality in the Cardiac Arrhythmia Suppression Trial (CAST). *Circulation* 1994;90:2843-2852.
14. Carson PE, Bourge RC, DiBianco R: Advances in Heart Failure Therapy. *Federal Practitioner* 1995;December 12(supplement):20-22.
15. Carson PE, Johnson GR, Fletcher RD, Cohn JN for the V-HeFT Cooperative Studies Group: Mild Systolic Dysfunction Heart Failure (LVEF >35%): Baseline Characteristics, Prognosis, Response to Therapy. *J Am Coll Cardiol* 1996;27:642-9.
16. Boden WE, Ziesche S, Carson PE, Conrad CH, Syat D, Cohn JN for the V-HeFT III Investigators: Rationale and Design of the Third Vasodilator-Heart Failure Trial (V-HeFT III): Felodipine as Adjunctive Therapy to Enalapril and Loop Diuretics with or without Digoxin in Chronic Congestive Heart Failure. *Am J Cardiol* 1996; 77:1031-1036
17. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL for the Prospective Randomized Amlodipine Survival Evaluation Study Group: Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure. *N Engl J Med* 1996;335:1107-14.
18. Carson PE: Pharmacologic treatment of congestive heart failure. *Clin Cardiol* 1996; Apr;19(4):271-7
19. Carson PE, Strauss WE, Morrison DA, Boden WG: Management of Ischemic Heart Disease for Primary Care. *Federal Practitioner* March 1997;14:4-25.
Carson PE: Beta-Blocker Therapy in Heart Failure Cardiology Annual of Drug therapy. 1997;Vol 1:1-10
20. Singh SN, Fisher SG, Carson PE, Fletcher RD. Nonsustained ventricular tachycardia in severe heartfailure.Circulation. 1997 Nov 18;96(10):3794-5.
21. Ferry DR, O'Rourke RA, Blaustein AS, Crawford MH,

Deedwania PC, Carson, PE, Pepine CJ, Thomas RG, Hlatky MA, Leppo JA, Iwane MK, Kleiger RE, Zoble RG, Dai H, Chow BK, Lavori PW, Boden WE For the VANQWISH Trial Research Investigators: Design and Baseline Characteristics for the Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital (VANQWISH) Trial. *JACC* 1998;31:312-20.

22. O'Connor CM, Carson PE, Belkin RN, Cropp AB, Frid DJ, Miller AB, Neuberg GW, Pressler ML, Wertheimer H, Packer M for The PRAISE Investigators: Effect of Amlodipine on Mode of Death in Severe Chronic Heart Failure: The PRAISE Trial. *American Journal of Cardiology* 1998; 82:881-88.

23. Singh SN, Fisher SG, Carson PE, Fletcher RD and The Department of Veterans Affairs CHF STAT Investigators. Prevalence and significance of non-sustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. *J Am Coll Cardiol* 1998; 32:942-947.

24. Carson PE. *Beta Blocker Treatment in Heart Failure. Progress in Cardiovascular Diseases* 1999; 41:301-322.

25. Carson, PE. B-Blocker Therapy in Heart Failure: Pathophysiology and Clinical Results. Current Problems in Cardiology. *Cardiology* 1999; 24:421-460.

26. Russell SD, Koshkarian GM, Medinger AE, Carson PE, Higginbotham MB. Lack of Effect of Increased Inspired Oxygen Concentrations on Maximal Exercise Capacity or Ventilation in Stable Heart Failure. *American Journal of Cardiology* 1999; 84:1412-1416.

27. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial Differences in the Outcome of Left Ventricular Dysfunction. *N Engl J Med* 1999; 340:609-616.

28. Young SO, Holubkov R, Loftus S, Bourge R, Carson P, Jaski B, White BG, Feldman AM. Effect of inotrope withdrawal on morbidity and mortality in patients with chronic heart failure: results of the vesnarinone trial withdrawal substudy. Vest Withdrawal Substudy Group. *J Card Fail* September 1999; 5(3): 195-200; discussion 201-202.

29. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-

heart failure trials. Vasodilator-Heart Failure Trial Study Group. *J Card Fail* September 1999; 5 (3): 178-87.

30. Carson PE, O'Connor CM, Miller AB, Anderson S, Belkin RN, Neuberger GW, Wertheimer JH, Frid DJ, Cropp A, Packer M. Circadian Rhythm and Sudden Death in Heart Failure: Results From PRAISE. *JACC* August 2000.

31. Carson PE. Rationale for the use of combination ACE inhibitor/ARB therapy in heart failure. *American Heart Journal* Sept. 2000; 140:361-366.

32. Carson PE, The HF epidemic: The need for new treatment strategies: *JRAAS* 2000; 1(Suppl 2):32-4.

33. Carson, PE, B-Blocker Therapy in Heart Failure: Drug Therapy In Cardiovascular Disease May *Cardiology Clinic* 2000; 19; (2) 2-1 – 2-11.

34. Carson PE, Giles T, Higginbotham M, Hollenberg N, Kannel W, O'Connor C, Siragy HM. Angiotensin Receptor Blockers: Evidence for Preserving Target Organs: *Clinical Cardiology Clin Cardiol*. 2001 Mar;24(3):183-90

35. BEST Investigators (STEERING Committee), A Trial of the Beta-Blocker Bucindolol in Patients with Chronic Heart Failure: *NEJM* 2001;344; 1659-1667

36. Neuberger GW, Miller AB, O'Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML, Wertheimer JH, Packer M; PRAISE Investigators. Prospective Randomized Amlodipine Survival Evaluation: Diuretic resistance predicts mortality in patients with advanced heart failure. *Am Heart J*. 2002 Jul;144(1):31-8.

37. Carson P, Tognoni G, Cohn JN, Effect of Valsartan on hospitalization: results from ValHeFT. *J Card Fail*. 2003 June;9(3):164-71

38. Bristow M. R., Saxon L. A., Boehmer J., Krueger S., Kass D. A., De Marco T., Carson P., DiCarlo L., DeMets D., White B. G., DeVries D. W., Feldman A. M., the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators :Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure *N Engl J Med* 2004; 350:2140-2150

39. Taylor A. L., Ziesche S., Yancy C., Carson P., D'Agostino R. Jr., Ferdinand K., Taylor M., Adams K., Sabolinski M., Worcel M., Cohn J.N. The African-American Heart Failure Trial Investigators: Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure *N Engl J Med* 2004; 351:2049-2057
40. Krum H, Carson P, Farsang C, Maggioni AP, Glazer Rd, Aknay C, Chiang YT, Cohn JN. Effect of valsartan added to background ACE Inhibitor therapy In patients with heart failure: results from Val-HeFT. *Eur J Heart Failure* 2004; 7:937-45
41. O'Connor CM, Gottlieb S, Bourque JM, Krause-Steinrauf H, Anand I, Anderson JL, Plehn JF, Silver MA, White M, Carson P; BEST Investigators.
Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. *Am J Cardiol.* 2005 Mar 1;95(5):558-64.
42. Maggioni AP, Latini R, Carson PE, Singh SN, Barkers S, Glazer R, Masson S, Cere E, Tognoni G, Cohn JN Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Trial (Val-HeFT). *American Heart Journal* 2005; Vol 149:548-57
43. Carson P, Massie BM, McKelvie R, McMurray J, Komajda M, Zile M, Ptaszynska A, Frangin G. for the I-PRESERVE investigators The Irbesartan in Heart Failure with Preserved Systolic Function(I-PRESERVE) Trial: Rationale and Design *Journal of Cardiac Failure* 2005; 11: 576-585
44. Carson P, Anand I, Jaski B, Steinberg J, Lwin A, Lindenfeld J, Ghali J, O'Connor C, Bristow M, Feldman A. MODE OF DEATH IN ADVANCED IN HEART FAILURE - THE COMPANION TRIAL *J Am Coll Cardiol.* 2005 Dec 20;46(12):2329-34.
45. Feldman AM, de Lissovoy G, Bristow MR, Saxon LA, De Marco T, Kass Da, Boehmer J, Singh S, Whellan DJ, Carson P, Boscoe A, Baker TM, Gunderman MR. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. *JACC* 2005, Dec 20;46(12):2311-21.
46. Cohn JN, Carson PE, O'Connor C, Opasich C, Pina IL, Scherillo M, Sinagra G, Warner-Stevenson L, Tristani FE, Volpi A. Prognosis and mechanism of death in treated heart failure: data from the

placebo arm of Val-HeFT.. Congestive Heart Failure. 2006 May – June;12(3):127-31

47. Saxon LA, Bristow MR, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, Feldman AM, Galle E, Ecklund F. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation. 2006 Dec 19;114(25):2766-72.

48. Lindenfeld J, Feldman A, Saxon L, Boehmer J, Carson P, Ghali J, Anand I, Singh S, Steinberg J, Jaski B, DeMarco T, Mann D, Yong P, Galle E, Ecklund F, Bristow M. Effects of Cardiac Resynchronization Therapy With or Without a Defibrillator on Survival and Hospitalizations in Patients with NYHA Class IV Heart Failure. Circulation. 2007 Jan 16; 115(2):204-12.

49. Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, Adams K, Olukotun AY, Ofili E, Tam SW, Sabolinski ML, Worcel M, Cohn JN on behalf of the African-American Heart Failure Trial Investigators Early and Sustained Benefit on Event-Free Survival and Heart Failure Hospitalization From Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine: Consistency Across Subgroups in the African-American Heart Failure Trial. Circulation 2007 115: 1747 - 1753;

50. Feldman AM, Oren RM, Abraham WT, Boehmer JP, Carson PE, Eichhorn E, Gilbert EM, Kao A, Leier CV, Lowes BD, Mathier MA, McGrew FA, Metra M, Zisman LS, Shakar SF, Krueger SK, Robertson AD, White BG, Gerber MJ, Wold GE, Bristow MR; EMOTE Study Group. Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial. Am Heart J. 2007 Nov;154(5):861-9

51. Mozaffarian D, Anker SD, Anand I, Linker DT, Sullivan MD, Cleland JG, Carson PE, Maggioni AP, Mann DL, Pitt B, Poole-Wilson PA, Levy WC. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation. 2007 Jul 24;116(4):392-8.

52. Ghali JK, Boehmer J, Feldman AM, Saxon LA, Demarco T, Carson P, Yong P, Galle EG, Leigh J, Ecklund FL, Bristow MR. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure. J Card

Fail. 2007 Nov;13(9):769-73.

53. McMurray JV, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska A, Staiger C, Donovan MJ, Massie BM. Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I-PRESERVED trial. *The European Journal of Heart Failure* 2008;10; 149 -156.

54. Abraham WT, Burkhoff D, Nademanee K, Carson P, Bourge R, Ellenbogen KA, Parides M, Kadish A; FIX-HF-5 Investigators and Coordinators. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. *Am Heart J.* 2008 Oct;156(4):641-648

55. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. Irbesartan in patients with heart failure and preserved ejection fraction. *N Engl J Med* 2008;359:2456-2467

56. Anand IS, Carson P, Galle E, Song R, Boehmer J, Ghali JK, Jaski B, Lindenfeld J, O'Connor C, Steinberg JS, Leigh J, Yong P, Kosorok MR, Feldman AM, DeMets D, Bristow MR. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. *Circulation.* 2009 Feb 24;119(7):969-77

57. Amato JL Jr, Amato JL Sr, Ghali JK, Tomoda H, Schillaci G, Pucci G, Pirro M, Massie BM, Carson PE. Irbesartan in patients with heart failure and preserved ejection fraction. *N Engl J Med* 360:1256, March 19, 2009 *Correspondence*

58. Sumner AD, Boehmer JP, Saxon LA, Carson P, Feldman AM, Galle E, Bristow MR. *Congest Heart Fail.* 2009 Jul-Aug;15(4):159-64 Statin use is associated with improved survival in patients with advanced heart failure receiving resynchronization therapy.

59. Carson P, Tam SW, Ghali J K., Archambault WT, , Taylor A, Cohn JN, Braman VM, Worcel M, Anand IS. Relationship of Quality of Life Scores with Baseline Characteristics and Outcomes in the African-American Heart Failure Trial. *J Card Fail* 2009; 15: 835-842

60. McKelvie RS, Carson PE, Komajda M, McMurray J, Zile M, Ptaszynska A, Donovan M, , Massie BM, for the I-PRESERVE

Investigators. Baseline Plasma NT-proBNP And Clinical Characteristics: Results From The Irbesartan In Heart Failure With Preserved Ejection Fraction Trial *J Card Fail* 2010; 16: 128-134

61. Zile MR, Gaasch, Anand IS, Haass M, Little WC, Miller AB, Lopez-Sendon J, Teerlink JR, White M, McMurray JJ, Komajda M, McKelvie R, Ptaszynska A, Hetzel SJ, Massie BM, Carson PE for the I-Preserve Investigators. Mode of Death in Patients with Heart Failure and a Preserved Ejection Fraction: Results from Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-Preserve) Trial *Circulation* 2010; 121: 1393-1405

62. Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, Demets D, Massie BM: Factors Associated with Outcome in Heart Failure with Preserved Ejection Fraction: Findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). *Circ Heart Fail*, 2010, Nov 10. [Epub ahead of print].

63. Carson P, Fiuzat M, O'Connor C, Anand I, Plehn J, Lindenfeld J, Silver M, White M, Miller A, Davis G, Robertson A, Bristow M, Gottlieb S. Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β -Blocker Evaluation of Survival Trial [BEST]) *American Heart Journal* 2010 Vol. 160, Issue 4, Pages 649-654

64. O'Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, Carson P, Haass M, Hauptman PJ, Metra M, Oren RM, Patten R, Piña I, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghide M; Efficacy of Vasopressin Antagonism in heart Failure Outcome Study with Tolvaptan (EVEREST) investigators. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. *Am Heart J*. 2010 May;159(5):841-849.e1

65. Butler J, Anand IS, Kuskowski MA, Rector T, Carson P, Cohn JN; Val-HeFT Investigators. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). *Congest Heart Fail*. 2010 Sep-Oct;16(5):191-5. doi: 10.1111/j.1751-7133.2010.00161.x

66. Wu AH, Ghali JK, Neuberger GW, O'Connor CM, Carson PE, Levy WC. Uric acid level and allopurinol use as risk markers of

mortality and morbidity in systolic heart failure. *Am Heart J.* 2010 Nov;160(5):928-33.

67. Kadish A, Nademanee K, Volosin K, Krueger S, Neelagaru S, Raval N, Obel O, Weiner S, Wish M, Carson P, Ellenbogen K, Bourge R, Parides M, Chiacchierini RP, Goldsmith R, Goldstein S, Mika Y, Burkhoff D, Abraham WT. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. *Am Heart J.* 2011 Feb;161(2):329-337.e1-2

68. Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, Carson PE. Body Mass Index and Adverse Cardiovascular Outcomes in Heart Failure Patients with Preserved Ejection Fraction: Results from the I-PRESERVE Trial. *Circ Heart Fail.* 2011 *Circ Heart Fail.* 2011;4:324-331

69. Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, McMurray JJ, Zile M, Komajda M, Massie B, Carson PE Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction: Findings from the I-PRESERVE Trial *Circ Heart Fail* 2011/ Published online before print June 29, 2011, doi: 10.1161/

70. Krum H, Maros E, Schneider HG, Ptaszynska A, Black M, Carson PE, Komajda M, Massie BM, McKelvie R, McMurray JJ, Zile MR, Anand I. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. *Circ Heart Fail.* 2011;4:561-568

71. O'Connor CM, Fiuzat M, Swedberg K, Caron M, Koch B, PE. Carson, Gattis-Stough W, Davis GW, Bristow MR Influence of Global Region on Outcomes in Heart Failure Beta-Blocker Trials *Journal of the American College of Cardiology* Volume 58, Issue 9, 23 August 2011, 915-922

72. O'Connor CM, Fiuzat M, Lindenfeld J, Miller A, Lombardi C, Carson P, Shaw LK, Wang LJ, Connolly P, Mills R, Yancy C, Mahaffey . Mode of Death and Hospitalization from the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) Trial and

Comparison of Clinical Events Committee Adjudicated Versus Investigator Reported Outcomes Am J Cardiol. 2011 Sep 3

73. Abraham WT, Nademanee K, Volosin K, Krueger S, Neelaguru S, Raval N, Obel O, Weiner S, Wish M, Carson P, Ellenbogen K, Bourge R, Parides M, Chiacchierini RP, Goldsmith R, Goldstein S, Mika Y, Burkhoff D, Kadish A; FIX-HF-5 Investigators and Coordinators. Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. J Card Fail. 2011 Sep;17(9):710-7.

74. Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, Baicu CF, Massie BM, Carson PE, for the I-PRESERVE Investigators. Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients with Heart Failure and a Preserved Ejection Fraction. Circulation Heart Failure Circulation. 2011 Dec 6;124(23):2491-501.

75. Rector TS, Carson PE, Anand IS, McMurray JJ, Zile MR, McKelvie RS, Komajda M, Kuskowski M, Massie BM. Assessment of Long-term Effects of Irbesartan on Heart Failure with Preserved Ejection Fraction as Measured by the Minnesota Living with Heart Failure Questionnaire in the I-PRESERVE Trial. Circ Heart Fail. 2012 Jan 20

76. Stevenson WG, Hernandez AF, Carson PE, Fang JC, Katz SD, Spertus JA, Sweitzer NK, Tang WH, Albert NM, Butler J, Westlake Canary CA, Collins SP, Colvin-Adams M, Ezekowitz JA, Givertz MM, Hershberger RE, Rogers JG, Teerlink JR, Walsh MN, Stough WG, Starling RC. Indications for cardiac resynchronization therapy: 2011 update from the heart failure society of america guideline committee. J Card Fail. 2012 Feb;18(2):94-106

77. Teerlink JR, Iragui VJ, Mohr JP, Carson PE, Hauptman PJ, Lovett DH, Miller AB, Piña IL, Thomson S, Varosy PD, Zile MR, Cleland JG, Givertz MM, Metra M, Ponikowski P, Voors AA, Davison BA, Cotter G, Wolko D, Delucca P, Salerno CM, Mansoor GA, Dittrich H, O'Connor CM, Massie BM. The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT Drug Saf. 2012 Mar 1;35(3):233-44

78. Butler J, Ezekowitz JA, Collins SP, Givertz MM, Teerlink JR, Walsh MN, Albert NM, Westlake Canary CA, Carson PE, Colvin-

Adams M, Fang JC, Hernandez AF, Hershberger RE, Katz SD, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Stough WG, Starling RC. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction heart failure society of america guidelines committee. J Card Fail. 2012 Apr;18(4):265-81

79. Abramov, D, Carson, PE. The Role of Angiotensin Receptor Blockers in reducing the risk of cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2012 Sep;13(3):317-27

80. Lam CS, Carson PE, Anand IS, Rector TS, Kuskowski M, Komajda M, McKelvie RS, McMurray JJ, Zile MR, Massie BM, Kitzman DW. Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients with Heart Failure and Preserved Ejection Fraction: The I-PRESERVE Trial Circ Heart Fail. 2012 Sep 1;5(5):571-8.

81. O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Walsh R, Nelson P, Medway A, Davis G, Robertson AD, Port JD, Carr J, Murphy GA, Lazzeroni LC, Abraham WT, Liggett SB, Bristow MR. Combinatorial pharmacogenetic interactions of bucindolol and β_1 , α_2C adrenergic receptor polymorphisms. PLoS One. 2012;7(10).

82. Rho RW, Patton KK, Poole JE, Cleland JG, Shadman R, Anand I, Maggioni AP, Carson PE, Swedberg K, Levy WC. Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator. Circulation. 2012 Nov 13;126(20):2402-7

83. Kao DP, Davis G, Aleong R, O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Murphy GA, Sauer W, Bristow MR. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. J Card Fail. 2013 Aug;19(8):592-9.

84. Wu AH, Levy WC, Welch KB, Neuberg GW, O'Connor CM, Carson PE, Miller AB, Ghali JK. Association Between Bilirubin and Mode of Death in Severe Systolic Heart Failure Am J Cardiol. 2013 Jan 23. doi:pii: S0002-9149(12)02651-3.

85. Givertz MM, Teerlink JR, Albert NM, Westlake Canary CA, Collins SP, Colvin-Adams M, Ezekowitz JA, Fang JC, Hernandez AF, Katz SD, Krishnamani R, Stough WG, Walsh MN, Butler J,

Carson PE, Dimarco JP, Hershberger RE, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Starling RC. Acute decompensated heart failure: update on new and emerging evidence and directions for future research. *J Card Fail.* 2013 Jun;19(6):371-89

86. Carson PE. Editorial: Identifying Heart Failure Hospitalizations Can an Automated Algorithm Become a Gold Standard? *Circulation: Heart Failure.* 2013; 6: 621-623

87. Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O'Connor C, Rouleau JL, Schocken D, Anderson SA, DeMets DL; PRAISE-2 Study Group. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). *JACC Heart Fail.* 2013 Aug;1(4):308-14..

88. Böhm M, Perez A, Jhund P, Reil JC, Komajda M, Zile MR., McKelvie R, Anand S., Massie BM., Carson PE., McMurray JJV. Relationship between heart rate and mortality and morbidity in the irbesartan in patients with heart failure and preserved systolic function trial (I-Preserve). *Eur J Heart Fail.* 2014 Jul;16(7):778-87

89. Carson PE, Miller A, O'Connor CM., Pina IL., Selzman C, Sueta C, Wertheimer J, Lee KL., She L, Greene D, Jones RH., Velazquez EJ. for the STICH investigators Surgical Treatment for Ischemic Heart Failure (STICH) Trial: Mode of Death Results. *JACC Heart Fail.* 2013 Oct;1(5):400-8

90. Damman K, Perez AC, Anand IS, Komajda M, McKelvie RS, Zile MR, Massie B, Carson PE, McMurray JJ. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. *J Am Coll Cardiol.* 2014 Sep 16;64

91. Oluleye OW, Rector TS, Win S, McMurray JJ, Zile MR, Komajda M, McKelvie RS, Massie B, Carson PE, Anand IS. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. *Circ Heart Fail.* 2014 Nov;7(6):960-6

92. Adabag S, Rector TS, Anand IS, McMurray JJ, Zile M, Komajda M, McKelvie RS, Massie B, Carson PE. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. *Eur J Heart Fail*. 2014 Nov;16(11):1175-82
93. Bhatia V, Bajaj NS, Sanam K, Hashim T, Morgan CJ, Prabhu SD, Fonarow GC, Deedwania P, Butler J, Carson P, Love TE, Kheirbek R, Aronow WS, Anker SD, Waagstein F, Fletcher R, Allman RM, Ahmed A. Beta-Blocker Use and 30-Day All-Cause Readmission in Medicare Beneficiaries with Systolic Heart Failure *Am J Med*. 2014 Dec 29. pii: S0002-9343
94. Kristensen SL, Køber L, Jhund PS, Solomon SD, Kjekshus J, McKelvie RS, Zile MR, Granger CB, Wikstrand J, Komajda M, Carson PE, Pfeffer MA, Swedberg K, Wedel H, Yusuf S, McMurray JJ International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. *Circulation*. 2015 Jan 6;131(1):43-53
95. Kristensen SL, Jhund PS, Køber L, Preiss D, Kjekshus J, McKelvie RS, Zile MR, Anand IS, Wikstrand J, Wedel H, Komajda M, Carson PE, Cleland JG, McMurray JJ Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. *Eur J Heart Fail*. 2015 Feb;17(2):169-76
96. Carson PE, Anand Is, Win S, Rector TS, Haass M, Lopez-Sendon J, Miller A, Teerlink J, White M, Komajda M, Michael Zile M, McMurray JJ, Massie BM The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure with Preserved Ejection Fraction: Results from the I-Preserve Trial *JACC Heart Fail*. 2015 (In Press)
97. Kristensen SL, Jhund PS, Køber L, McKelvie RS, Zile MR, Anand IS, Komajda M, Cleland J, Carson PE, McMurray JJV, Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction *JACC Heart Fail*. 2015 (In Press)
98. Jhund PS, Anand IS, Komajda M, Claggett BL, McKelvie RS, Zile MR, Carson PE, McMurray JJV Changes in N-terminal pro brain natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study

Eur J Heart Fail. (in Press)

99. Fang JC, Ewald GA, Allen LA, Butler J, Westlake Canary CA, Colvin-Adams M, Dickinson MG, Levy P, Stough WG, Sweitzer NK, Teerlink JR, Whellan DJ, Albert NM, Krishnamani R, Rich MW, Walsh MN, Bonnell MR, Carson PE, Chan MC, Dries DL, Hernandez AF, Hershberger RE, Katz SD, Moore S, Rodgers JE, Rogers JG, Vest AR, Givertz MM. Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee.

J Card Fail. 2015 Jun;21(6):519-34

100. Colvin M, Sweitzer NK, Albert NM, Krishnamani R, Rich MW, Stough WG, Walsh MN, Westlake Canary CA, Allen LA, Bonnell MR, Carson PE, Chan MC, Dickinson MG, Dries DL, Ewald GA, Fang JC, Hernandez AF, Hershberger RE, Katz SD, Moore S, Rodgers JE, Rogers JG, Vest AR, Whellan DJ, Givertz MM.

Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee. J Card Fail. 2015 Aug;21(8):674-93

101. Badar AA, Perez-Moreno AC, Hawkins NM, Jhund PS, Brunton AP, Anand IS, McKelvie RS, Komajda M, Zile MR, Carson PE, Gardner RS, Petrie MC, McMurray JJ. Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial. Circ Heart Fail. 2015 Jul;8(4):717-24

102. Shadman R, Poole JE, Dardas TF, Mozaffarian D, Cleland JG, Swedberg K, Maggioni AP, Anand IS, Carson PE, Miller AB, Levy WC A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model. Heart Rhythm. 2015 Jun 30. pii: S1547-5271

103. Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, McKelvie RS, Komajda M, McMurray JJ, Lindenfeld J. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015 Aug 6. doi: 10.1002/ejhf.327. [Epub ahead of print]

104. Cannon JA, Shen L, Jhund PS, Anand IS, Komajda M, McKelvie RS, Zile MR, Carson PE, McMurray JJ Clinical outcomes

according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial.

Eur J Heart Fail. 2016 Aug;18(8):1021-31

105. Gandhi PU, Chow SL, Rector TS, Krum H, Gaggin HK, McMurray JJ, Zile MR, Komajda M, McKelvie RS, Carson PE, Januzzi JL Jr, Anand IS.

Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. J Card Fail. 2016 Jun 16. pii: S1071-9164(16)30109-9.

106. Petrie MC, Jhund PS, She L, Adlbrecht C, Doenst T, Panza JA, Hill JA, Lee KL, Rouleau JL, Prior DL, Ali IS, Maddury J, Golba KS, White HD, Carson P, Chrzanowski L, Romanov A, Miller AB, Velazquez EJ; STICH Trial Investigators.

Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure).

Circulation. 2016 Nov 1;134(18):1314-1324

107. Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, Køber L, McKelvie RS, Zile MR, Anand IS, Komajda M, Gottdiener JS, Carson PE, McMurray JJ.

Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).

Circulation. 2017 Feb 21;135(8):724-735.

/CIRCULATIONAHA. 2017 Jan 4

108. Abdul-Rahim AH, Perez AC, MacIsaac RL, Jhund PS, Claggett BL, Carson PE, Komajda M, McKelvie RS, Zile MR, Swedberg K, Yusuf S, Pfeffer MA, Solomon SD, Lip GYH, Lees KR, McMurray JJV; Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.

Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity-Preserved (CHARM-Preserved) and the Irbesartan in Heart Failure with Preserved Systolic Function (I-Preserve) Steering Committees

Eur Heart J. 2017 Mar 7;38(10):742-750

\

109. Carson PE.
Natriuretic Peptide Levels and Interaction With Treatment in HFpEF: Intriguing Findings in a "House of Cards"?
JACC Heart Fail. 2017 Apr;5(4):253-255

110. Carson PE.
Redefining "Winning" and Its Implications in Heart Failure Clinical Trials.
JACC Heart Fail. 2017 Aug;5(8):600-602.

111. Seltzer JH, Heise T, Carson P, Canos D, Hiatt JC, Vranckx P, Christen T, Cutlip DE
Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium.
.Am Heart J. 2017 Aug;190:76-85. doi: 10.1016/j.ahj.2017.05.009.
Epub 2017 May 28. Review

112. Abraham WT, Kuck KH, Goldsmith RL, Lindenfeld J, Reddy VY, Carson PE, Mann DL, Saville B, Parise H, Chan R, Wiegand P, Hastings JL, Kaplan AJ, Edelmann F, Luthje L, Kahwash R, Tomassoni GF, Gutterman DD, Stagg A, Burkoff D, Hasenfuß GA
Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation.
JACC Heart Fail. 2018 Oct;6(10):874-883. doi: 10.1016/j.jchf.2018.04.010. Epub 2018 May 10.

113. Carson PE.
Trying to Make Progress on Survival in a Complicated Area: Sudden Death in HFpEF.
JACC Heart Fail. 2018 Aug;6(8):662-664

114.. Ambrosy AP, Stevens SR, Al-Khalidi HR, Rouleau JL, Bouabdallaoui N, Carson PE, Adlbrecht C, Cleland JGF, Dabrowski R, Golba KS, Pina IL, Sueta CA, Roy A, Sopko G, Bonow RO, Velazquez EJ; STICH Trial Investigators.
Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy
Eur J Heart Fail. 2019 Mar;21(3):373-381

115. Kristensen SL, Mogensen UM, Jhund PS, Rørth R, Anand IS, Carson PE, Desai AS, Pitt B, Pfeffer MA, Solomon SD, Zile MR, Køber L, McMurray JJV. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure

and Preserved Ejection Fraction According to Atrial Fibrillation Status

Circ Heart Fail. 2019 Mar;12(3)

116. Shen L, Jhund PS, Docherty KF, Petrie MC, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Swedberg K, Zile MR, McMurray JJV.

Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction

JACC Heart Fail. 2019 May;7(5):418-427.

117. Shen L, Rørth R, Cosmi D, Kristensen SL, Petrie MC, Cosmi F, Latini R, Køber L, Anand IS, Carson PE, Granger CB, Komajda M, McKelvie RS, Solomon SD, Staszewsky L, Swedberg K, Huynh T, Zile MR, Jhund PS, McMurray JJV

Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction

Eur J Heart Fail. 2019 Aug;21(8):974-984

118. Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Køber L, Swedberg K, Zile MR, Pitt B, Lam CSP, McMurray JJV
Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction

J Am Coll Cardiol. 2019 Aug 6;74(5):601-612

Books or Chapters in books, and publications in other journals

1. Carson PE. Neurohormonal Antagonists in Relation to Sudden Death in Heart Failure: Elsevier Saunders. The Curtis Center, Philadelphia, Pennsylvania 2005. Page 249 – 258.

Abstracts

List authors in order of appearance on paper: Last name, Initials, Title, *Journal name*, volume: first and last page numbers, year.

1. Carson PE, Carlyle PF, Carlyle W, Echhoff P, Cohn JN: Effect of Myocardial Damage on the Sympathetic Nervous System in Dogs. *Clinical Research* 1985;33:865A.

2. Carson PE, Carlyle PF, Cohn JN: Cardiac and Regional Vascular Effects of Atrial Natriuretic Peptide in Awake Dogs. *Clinical Research* 1986;34:707A.

3. Carson PE, Carlyle PF, Hostetter TH, Cohn JN: Hemodynamic, Neurohumoral and Renal Responses to Atrial Natriuretic Peptide in Conscious Dogs. Am Soc Hypertension: BAAP Congress 1:102A.
4. Carson PE, Fletcher RD, Johnson G, Cohn JN: Atrial Fibrillation/Flutter Does Not Decrease Survival in Congestive Heart Failure. *J Am Coll Cardiol* 1991;17:90A.
5. Platia EJ, Henthorn RW, Pawetan Y, Buckingham T, Carlson MD, Anderson TL, Carson PE: Cardiac Arrhythmia Suppression Trial (CAST) Baseline Predictors of Highest Mortality. *J Am Coll Cardiol* 1991;17:230A.
6. Carson PE, Johnson G, Cohn JN for the VA Cooperative Study Group: Predictors of a Preferential Survival Benefit of Converting Enzyme Inhibitors vs. Vasodilators in Heart Failure. *Circulation* 1992;86(suppl):I-252.
7. Dunkman WB, Johnson GR, Carson PE, Cohn JN for the V-HeFT Study Group: Incidence of Thromboembolic Events in Congestive Heart Failure. *Circulation* 1992(suppl);86:I-252.
8. Fletcher RD, Carson PE, Johnson GR, Cintron G and the V-HeFT Investigators. Effects of Ventricular Tachycardia at Baseline on Response to Vasodilator Therapy in Congestive Heart Failure. *Circulation* 1992;86(suppl):I-586.
9. Carson PE, Johnson G, Dunkman WB, Fletcher RD, Cohn JN for the V-HeFT Study Group: The Influence of Atrial Fibrillation on Prognosis in Mild-Moderate Heart Failure. *Circulation* 1992(suppl);86:I-664A.
10. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, White BG: Results of a Multicenter Study of OPC-8212 in Chronic Congestive Heart Failure. *Circulation* 1992(suppl);86:I-374.
11. Carson PE, Johnson G, Fletcher RD, Cohn J and the VA Cooperative Study Group: Mild Systolic Dysfunction (EF>35%): Baseline Characteristics and Therapeutic Response in V-HeFT. *J Am Coll Cardiol* 1993;21:131A.
12. Carson PE, Johnson G, Cohn J and the V-HeFT Study Group: Intense Sympathetic Activation with Mild Symptoms in Heart Failure: Effect of Therapy in V-HeFT II. *Journal of Heart Failure* 1993;1:290.

13. Carson PE, Colucci WS, Deedwania PC, Uretsky BF, Bristow MR, Feldman AM, Cowart TD for the Vesnarinone Investigators: Lack of Proarrhythmia Reduction by Vesnarinone in Advanced Heart Failure. *Circulation* 1993;88:3240.
14. Carson PE, Johnson GR, Singh SN, Fletcher RD, Cohn JN for the VA Cooperative Study Group, Washington, DC, Minneapolis, MN: Differences in Vasodilator Response by Race in Heart Failure: V-HeFT. *J Am Coll Cardiol* 1994;23:382A.
15. Anderson JL, Hallstrom A, Platia EV, Carlson MD, Henthorn RW, Buckingham TA, Carson PE, for the CAST Investigators: Interaction of Baseline Characteristics and Moricizine on Risk of Mortality after Myocardial Infarction in the Cardiac Arrhythmia Suppression Trial (CAST). *Circulation* 1994;90(4):I-280.
16. Carson PE, Johnson GR, Fletcher RD, Cohn JN, and the V-HeFT VA Cooperative Studies Group. Prognostic Value of Serial Holter Monitors in Congestive Heart Failure: V-HeFT. *Circulation* 1994;90(4):I-339.
17. Carson PE, Higgenbotham M, White BG for the Vesnarinone Investigators: Peak Oxygen Uptake as a Predictor of Mortality in Heart Failure: Results from the Vesnarinone Multicenter Trial. *Journal of Heart Failure* 1995;2:1036.
18. Carson PE, Colucci WS, Deedwania PC, Uretsky BF, Bristow MR, Feldman AM, Cowart TD for the Vesnarinone Investigators: Lack of Proarrhythmia Reduction by Vesnarinone in Advanced Heart Failure. *European Heart Journal* 1995;2:A
19. Carson PE, Johnson G, Fletcher RD, Cohn J and the VA Cooperative Study Group: Mild Systolic Dysfunction (EF>35%): Baseline Characteristics and Therapeutic Response in V-HeFT. *European Heart Journal*
20. Carson PE, Johnson GR, Singh SN, Fletcher RD, Cohn JN for the Cooperative Study Group. Race and Hypertensive History Moderate Plasma Renin Activity and Therapeutic Response in Heart Failure: Vasodilator in Heart Failure Trial (VHeFT II). *Circulation* 1995;92(8):I-30.
21. Carson PE, Pressler M, Miller A, Anderson S, Belkin R, Frid D, Neuberger G, O'Connor C, Wertheimer J, Packer M, for the PRAISE Investigators: Circadian Rhythm and Sudden Death in Heart Failure:

Results From PRAISE. *JACC* 1996;25:280A

22. Pressler M, Carson PE, Miller AB, Wertheimer JH, O'Connor CM, Neuberger GW, Frid DJ, Belkin RN, Cropp AB, for the PRAISE Investigators. Safety of Amlodipine in Severe Heart Failure: Reduction of Sudden Death in Non-Ischemic Heart Disease. *JACC* 1996;25:281A

23. Feldman A, Young A, Bourge R, Carson P, Jaski B, DeMets D, White BG, Cohn JN, for the VEST Investigators: Mechanism of Increased Mortality From Vesnarinone in the Severe Heart Failure Trial (VesT). *JACC* 1997;29:64A

24. Russell SD, Koshkarian GM, Carson PE, Higginbotham MB: Failure of hyperoxia to improve maximal exercise capacity or to alter ventilatory responses in heart failure patients in a randomized, double blind, placebo controlled study. *JACC* 1997;29:528A

25. Neuberger G, Miller A, O'Connor C, Belkin R, Carson P, Cropp A, Frid D, Pressler M, Wertheimer J: Do clinical events predict subsequent mode of death in patients with advanced chronic heart failure? *JACC* 1998; 31:116A

26. Russo CA, Dai H, Chow BK, Lavori PW, O'Rourke RA, Crawford MH, Carson, PE, Lehmann, K, Boden WE: Favorable first year outcome among non-Q-wave myocardial infarction patients managed according to a non-invasive ischemia-guided strategy. *Circulation* 1998; Vol 18, No 17:3321

27. Neuberger G, O'Connor CM, Miller AB, Belkin RN, Carson PE, Cropp AB, Frid D, Nye R, Pressler ML, Wertheimer JH, Packer M: High diuretic doses are associated with sudden death in patients with advanced heart failure: The PRAISE Trial. *Circulation* 1998; Vol 18, No 17:1568

28. Dries DL, Exner DV, Domanski MJ, Carson PE, Gersh BJ: Increased Mortality in Black Compared to White Patients With Left Ventricular Systolic Dysfunction in the SOLVD Trials. *Circulation* 1998; Vol 98, No 17:4539

29. Carson PE, Anderson S, Xiroyin F, Young JB, Jaski BE, Bourge RC, Cohn JN. Predictors of Overall Mortality and Sudden Death in VEST. *Circulation* November 1999; 18: 1-678

30. Carson PE. Hemodynamic, Myocardial Functional and Neurohormonal Response to β -Blockade in Black vs. Non-Black

Patients in BEST. *Clinical Science October 2000; 102:3757*

31. Carson PE. Effect of β -Blockade on Mortality in African-Americans: The β -Blocker Evaluation of Survival Trial. *Clinical Science October 2000; 102:3759*

32. Eichhorn JE, Domanski MJ, Adams K, Bristow MR, Carson P, Yancy CW, Steinrauf-Krause: Hemodynamic, Myocardial Functional and Neurohormonal Responses to β -Blockade in Black vs Non-Black Patients in BEST. *Circulation 2000; Vol 102, No 18:3757.*

33. Eichhorn EJ, Domanski MJ, Adams K, Anderson JL, Bristow M, Carson P, Yancy CW, Krause-Steinrauf K: Effect of β -Blockade on Mortality in African-Americans: The β -Blocker Evaluation of Survival Trial. *Circulation 2000; Vol 102, No 18:3759*

34. Plehn JF, Krause-Steinrauf H, Anand IS, Gottlieb S, O'Connor CM, Silver MA, White M, Carson PE: Effect of Race on Cause-Specific Cardiovascular Mortality in Best. *Circulation 2000; Vol 102, No 18; 3764*

35. Samar Huma, Heggunde PS, Deedwania PC, Wade JM, Carson PE, Ferry DR, O'Rourke RA, Boden WE: Racial Differences in the Use of Invasive Cardiac Procedures and 1-Year Clinical Outcomes for Non-Q-Wave Myocardial Infarction Patients Randomized to Invasive vs. Conservative Management. *JACC 2001; 15A:1073-36*

36. Gottlieb SS, O'Connor C, Carson PE, Plehn JF, White M, Anand I, Silver M, Anderson JL, Krause-Steinrauf H: Low Incidence of Myocardial Infarction in the BEST Heart Failure Study. *JACC 2001; 178A:1168-67*

37. Carson PE, Fowler MB, Mohacsi P, Krum H, Tendera M, Coats AJ, Rouleau JL, Holclaw TL, Staiger C, Roecker EB, Amann-Zalan I, Packer M. Effect of Carvedilol in Black Patients with Severe Chronic Heart Failure Results of the COPERNICUS Study. *Circulation 2001; Vol 104, No 17:3550*

38. Cohn JN, Carson PE, Holwerda NJ, Stumpe K, Majahalme S, Maggioni A, Latini R, Tognoni G: Effect of Valsartan on Hospitalization Rate in Valsartan-Heart Failure Trial (Val-HeFT). *Circulation 2001; Vol 104, No 17: 2811*

39. Fowler MB, O'Connor CM, Carson P, Tendera M, Katus HA, Krum H, Mohacsi P, Coats AJ, Rouleau JL, Roecker EB, Amann-

Zalan I, Holsclaw T, Packer M. Effect of Carvedilol on Frequency and Severity of Hospitalization in Severe Chronic Heart Failure: Results of the COPERNICUS Study. *Circulation* 2001; Vol 104, No 17;3548

40. Carson PE, Cohn JN: Effect of Valsartan on Time-Adjusted and Hospitalization Frequency Rate in the Valsartan Heart Failure Trial. *JACC* 2002; 168A:1134-159

41. Carson P, Krum H, Cohn JN, on behalf of the Val-HeFT Invest, Washington, DC: The Effect of Baseline ACE Inhibitor Dose on the Efficacy of Valsartan In Val-HeFT. *Circulation* November 2002;Vol 106: 2522

42. Carson PE, Opasich C, Scherillo M, Sinagra G, Volpi A, O'Connor C, Tristani FE, Stevenson LW: Mechanism of Death In the Valsartan Heart Failure Trial. *European Heart Journal Supplement* 2003

43. Carson PE, O'Connor CM, Miller, Cohn JN, Department of Veterans Affairs Medical Center, Washington, DC: Hospitalization in Heart Failure: It's Not What You Think. *JACC* March 2004;Vol: 1069-107

44. Carson PE, Pina LL, Opasich C, O'Connor C, Tristani F, Stevenson LW, Hester A, Feliciano N, Aknay N, Veterans Affairs Medical Center, Washington, DC: Frequency Distribution of Hospitalized Heart Failure Patients: Data From The Adjudication Committee of ValHeFT. *JACC* March 2004;Vol 41: 1069-118

45. Kokkinos P, Greenberg M, Panagiotakos D, Chrysohoou C, Papademetriou V, Carson P, Lu D, Veterans Affairs Medical Center, Washington, DC, Georgetown University Medical Center, Washington, DC. *JACC* March 2004;Vol 43: 1161-60

46. Carson P, O'Connor C, Lindenfield J, Ghali J, Jaski B, Steinberg J, Barnet J, Anand I, Department of Veterans Affairs Medical Center, Washington, DC: Total Hospitalizations in Advanced Heart Failure: Results from COMPANION. *JACC* February 2005: Vol 45: 1075-150

47. Feldman AM, Lissovoy G, Bristow MR, Saxon LA, Marco T, Kass DA, Boehmer J, Singh S, Whellan DJ, Carson P, Boscoe A, Baker T, Gundeman MR, Jefferson Medical College, Philadelphia, PA, University of Colorado Health Science Center, Denver CO: Cost-Effectiveness of Cardiac-Resynchronization Therapy With and

Without a Defibrillator in COMPANION Heart Failure Patients.
JACC February 2005; Vol 45: 817-8.

48. Butler J, Anand I, Kuskowski M, Carson P, Hester A, Glazer R, Cohn J: Higher Mortality and Adverse Cardiovascular Outcomes Risk with Digoxin Use in Patients with Heart Failure: A ValHeFT substudy. *Scientific Session 2005; Vol 2; 641.*

49. Carson P, Ghali Jalal, Tam SW: Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine Improves Quality of Life in African Americans with Heart Failure: Results from African American Heart Failure Trial: *Scientific Session 2005; Vol 2: 643.*

50. Lindenfeld J, Feldman A, Saxon L, Boehmer J, Carson P, Ghali J, Steinberg J, DeMarco T, Mann D, Yong P, Galle E, Kcklund F: Cardiac Resynchronization Therapy with and without Defibrillator Improve Time to Death and Hospitalization in NYHA Class IV Heart Failure Patients. *Scientific Sessions 2005; Vol 2: 673.*

51. Carson P, Anand I, Ghali JK, Lindenfeld J, Miller AB, Tristani F, Braman VM, Worcel M, Sabolinski ML: Impact of Fixed-Combination of Isosorbide Dinitrate and Hydralazine on Heart Failure Progression in an African American Population: Focus on Mode of Death and Hospitalization. *Circulation October 2006; Vol 114:572.*

52. McKelvie RS, Komajda M, McMurray J, Zile M, Ptaszynska A, Bhaumik A, Carson P: Baseline Plasma NT-proBNP Concentrations in Relation to Clinical Characteristics: Results from the Irbesartan in Heart Failure with Preserved Systolic Function Trial. *Circulation Scientific Session 2006; Vol 2: 720.*

53. Ghali JK, Feldman AM, Saxon LA, DeMarco T, Carson P, Yong P, Galle E, Ecklund F, Bristow MR: The Influence of Diabetes on Outcome with Cardiac Resynchronization Therapy: Results from the COMPANION Trial. *Circulation October 2006; Vol 114: 764.*

54. Gottdiener JS, Massie BM, Carson PE, Bhaumik A, Komajda M, McKelvie R, McMurray J, Zile M: Cardiac Structural Changes and Diastolic Function in Heart Failure with Preserved Ejection Fraction – Importance of Left Atrial Volume: the iPRESERVE Study. *Circulation October 2006; Vol 114: 816.*

55. White M, Carson P, Anand IS, Gottlieb SS, Lindenfeld J, O'Connor C, Miller A, Plehn J, Silver MA, Robertson AD, Bristow MR: Effects of Bucindolol on Cardiovascular Mortality or

Morbidity are Determined by the Beta-1 389 Arg/Gly Receptor Polymorphism. *Circulation October 2007; Vol 116: 176.*

56. Anand IS, Carson P, Galle E, Song R, Boehmer J, Ghali J, Jaski B, Lindenfeld J, O'Connor C, Steinberg JS, Leigh J, Yong P, Kosorok MR, Feldman A, DeMets D, Bristow M: Cardiac Resynchronization Therapy Reduces the Risk of Hospitalizations in Patients with Advanced Heart Failure – Results From the COMPANION Trial. *Circulation October 2007; Vol 116: 334.*

57. Komajda M, McKelvie RS, McMurray JJ, Zile MR, Donovan M, Ptaszynska A, Massie BM, Carson P: Anaemia is Associated with Poor Outcome in Patients with Heart Failure and Preserved Ejection Fraction (HF PEF). Findings from the Irbesartan in Heart Failure with Preserved Systolic Function Trial (I-PRESERVE). *Circulation Scientific Session 2007; Vol 116: 551.*

58. McMurray JJ, Komajda M, McKelvie R, Zile M, Ptaszynska A, Massie BM, Carson PE: Renal Dysfunction is Associated with Increased Risk of Fatal and Non-fatal Cardiovascular Events in Patients with Heart Failure and Preserved Ejection Fraction – Findings From the Irbesartan in Heart Failure with Preserved Systolic Function Trial (I-Preserve). *Circulation October 2007; Vol 116: 552.*

59. Carson P, White M, Anand I, Plehn J, Gottlieb S, Silver M, Lindenfeld J, O'Connor C, O'Connor C, Miller A, Fiuzat M, Liggett SB, Davis G, Robertson AD, Bristow MR: Effect of β , 389 Arg/Gly α_{2C} 322-325 Wt/Del Genotypes on Adjudicated Hospitalizations in the BEST Trial. *Circulation October 2007; Vol 116: 649.*

60. Zile MR, Komajda M, McKelvie R, McMurray J, Donovan M, Ptaszynska A, Carson P, Massie BM: Atrial Fibrillation is Associated with Increased Risk of Fatal and Non-fatal Cardiovascular Events in Patients with Heart Failure and Preserved Ejection Fraction – Findings From the Irbesartan in Heart Failure with Preserved Systolic Function Trial (I-PRESERVED). *Circulation October 2007; Vol 116: 706.*

61. McKelvie RS, Komajda M, Massie BM, McMurray JJ, Zile MR, Donovan M, Ptaszynska A, Carson P: Diabetes Mellitus is Associated with Increased Risk of Fatal and Non-fatal Cardiovascular Events in Heart Failure Patients with Preserved Ejection Fraction – Findings From the Irbesartan in Heart Failure with Preserved Systolic Function Trial. *Circulation October 2007;*

Vol 116: 826.

62. Carson PE: Predictors of Outcome in Heart Failure With Preserved Ejection Fraction: One Year Findings From the Irbesartan in Heart Failure With Preserved Systolic Function Trial (I-PRESERVE). *JACC March 2008; Vol 51:A25.*

63. Carson PE, Taylor AL, Cohn JN, Ghall JK, Anand IS, Tam SW, Braman VM, Worcel M: Relationship of Quality of Life Scores with Baseline Characteristics and Outcomes in the African-American Heart Failure Trial. *JACC March 2008; Vol 51:A255.*

64. McMurray J, Rector T, Carson PE, Beusterien T, Komajda M, McKelvie R, Zile M, Ptaszynska A, Staiger C, Massie B: Health related quality of life in the Irbesartan in heart failure with preserved systolic function trial (I-PRESERVE). *European Heart Journal 2008; Vol 29:156.*

65. Zile MR, Gaasch WH, Anand I, Haass M, Little WC, Miller A, Lopez-Sendon J, Teerlink JR, White M, Carson PE: Mode of death in patients with heart failure and a preserved ejection fraction: results from Irbesartan heart failure with preserved ejection fraction study (I-PRESERVED) trial. *European Heart Journal 2009; Vol 30:867.*

66. Carson PE, Komajda M, Zile MR, McKelvie R, McMurray J, Hetzel S, Demets D, Staiger C, Ptaszynska A, Massie BM: Predictors of outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in heart failure with preserved ejection fraction trial (I-PRESERVED). *European Heart Journal 2009; Vol 30:865.*

67. Kadish AH, Nademanee K, Volosin K, Krueger S, Neelagaru S, Raval N, Obel O, Weiner S, Wish M, Carson PE, Ellenbogen K, Bourge R, Parides M, Chiaccheirine R, Goldsmith R, Goldstein S, Mika Y, Burkhoff D, and Abraham W Cardiac Contractility Modulation Improves Exercise Tolerance in NYHA Class III Patients With Narrow QRS and EF Between 25 and 35% A Subgroup Analysis of the FIX-HF-5 Study *Circulation, Nov 2009; 120: S824*

68. Carson PE, Komajda M, Zile M, Johnson RH, Hetzel S, McKelvie R, McMurray J, Staiger C, Ptaszynska A, and Massie B The Relation of Quality of Life Score to Outcome in Heart Failure With Preserved Ejection Fraction: Findings From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial (I-

PRESERVE) *Circulation*, Nov 2009; 120: S749

69. Kitzman DW, Haas MM, Carson PE, Hetzel S, Komajda M, Zile M, Johnson RH, McKelvie R, McMurray JJ, Demets D, Staiger C, Ptaszynska A, and Massie B Obesity and Its Relationship to Adverse Cardiovascular Outcomes in Older Patients With Heart Failure and Preserved Ejection Fraction in the (I-PRESERVE) Trial *Circulation*, Nov 2009; 120: S757 – S758

70. Carson PE, Zile M, McMurray J, McKelvie R, Komajda M, Hetzel S, DeMets D, Staiger C, Ptaszynska A, Massie B. Heart Failure with Preserved Ejection Fraction: Mortality Risk Post First Hospitalization Data from (I-PRESERVE) *JACC March 2010 Vol 53: A141.E1321*

71. Anand IS, Hetzel SJ, Miller AB, Carson PE, Gaasch WH, Haass M, Little WC, Lopez-Sendon J, Massie BM, McMurray JJ, Ptaszynska A, Teerlink JR, White M, Zile MR. Baseline Systolic Blood Pressure and Outcomes in Patients with Heart Failure and Preserved Ejection Fraction - Results from the I-Preserve Trial *JACC March 2010 Vol 55: A38.E365*.

72. Anand IS, Fiuzat M, O'Connor C, Lindenfeld J, Carson PE, Eicchorn E, Udelson J, Domanski M, Davis G, Bristow M, Impact of Baseline Volume Status And LVEF On All-Cause Mortality In The Best Trial *J. Am. Coll. Cardiol., March 2010; 55: A37.E360*

73. Krum H, Elsik M, Schneider HG, Ptaszynska A, Black M, Carson PE, and Massie B Peripheral Collagen Markers Predict All-Cause Mortality And Cardiovascular Hospitalization In Patients With Heart Failure and Preserved Ejection Fractions: Results of The I-PRESERVE Collagen Sub-Study *J. Am. Coll. Cardiol., March 2010; 55: A36.E344*.

74. Teerlink JR, Zile MR, White M, Miller AB, Lopez-Sendon J, Little WC, Haas M, Anand IS, Ptaszynska A, Hetzel SJ, Komajda M, McMurray JV, Massie BM, Carson PE, and I-Preserve Investigators
Acute Coronary Syndromes In Patients With Heart Failure With Preserved Ejection Fraction: A Harbinger of Death?
J. Am. Coll. Cardiol., March 2010; 55: A38.E368

75. Lam CS, Anand IS, Carson PE, Massie BM, Rector TS, Kuskowsik M, McKelvie RS, Zile MR, McMurray J, Komajda M, and Kitzman DW Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients with Heart Failure and Preserved

Ejection Fraction: The I-PRESERVE Trial *Circulation November 2011; 124:A10912*

76. Selcuk Adabag, Thomas Rector, John McMurray, Michael Zile, Michel Komajda, Robert McKelvie, Barry Massie, Peter Carson, and Inder S Anand A Prediction Model for Sudden Cardiac Death in Patients With Heart Failure and Preserved Ejection Fraction *Circulation*. 2014;130:A11043

77. Peter Carson, Inder Anand, Sithu Win, Michael Zile, Markus Haas, William Little, Alan Miller, Jose Lopez-Sendon, John Teerlink, Michel White, Michel Komajda, Robert S McKelvie, John J McMurray, and Barry Massie Why Are patients With Heart Failure and Preserved Ejection Fraction Hospitalized? Data From I-PRESERVE *Circulation*. 2013;128:A1584

78. Oludamilola Oluleye, Sithu Win, Thomas Rector, Michel Komadja, Michael Zile, Robert Mckelvie, John McMurray, Barry Massie, Peter Carson, and Inderjit Anand Risk of Clinical Outcomes and Baseline Atrial Fibrillation: Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial *Circulation*. 2013;128:A15893